FNAC of the Thyroid Following Carbimazole Therapy in Hyperthyroidism: A Diagnostic Dilemma

Oncology, Gastroenterology and Hepatology Reports Pub Date : 2018-04-10 DOI:10.5530/ogh.2018.7.1.7

T. Santosh, Hemlata Panwar, B. Kumari, Vandita Singh, R. Arora, Nighat Hussain

{"title":"FNAC of the Thyroid Following Carbimazole Therapy in Hyperthyroidism: A Diagnostic Dilemma","authors":"T. Santosh, Hemlata Panwar, B. Kumari, Vandita Singh, R. Arora, Nighat Hussain","doi":"10.5530/ogh.2018.7.1.7","DOIUrl":null,"url":null,"abstract":"Copyright © 2018 Phcog.Net. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license. Cite this article: Santosh T, Panwar H, Kumari B, Singh VY, Arora RD, Hussain N. FNAC of the Thyroid Following Carbimazole Therapy in Hyperthyroidism: A Diagnostic Dilemma. OGH Reports. 2018;7(1):38-40. ABSTRACT Antithyroid drug therapy is routinely used for treatment of hyperthyroid patients. Therapy induced changes in hyperthyroidism can cause serious diagnostic dilemma on FNAC and have been rarely documented. We present a case of 45-year-old female patient who clinically presented with diffuse thyroid swelling and features of hyperthyroidism. FNAC from thyroid swelling showed features of Hashimoto’s thyroiditis / Grave’s disease / Colloid goiter with follicular hyperplasia and at places raising the suspicion of malignant transformation. Further clinical evaluation of patient, it was found that she had carbimazole therapy. Correlating the clinical and cytomorphologic features, a diagnosis of “therapy induced (carbimazole) changes in hyperthyroidism was given.","PeriodicalId":166206,"journal":{"name":"Oncology, Gastroenterology and Hepatology Reports","volume":"121 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology, Gastroenterology and Hepatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5530/ogh.2018.7.1.7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Copyright © 2018 Phcog.Net. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license. Cite this article: Santosh T, Panwar H, Kumari B, Singh VY, Arora RD, Hussain N. FNAC of the Thyroid Following Carbimazole Therapy in Hyperthyroidism: A Diagnostic Dilemma. OGH Reports. 2018;7(1):38-40. ABSTRACT Antithyroid drug therapy is routinely used for treatment of hyperthyroid patients. Therapy induced changes in hyperthyroidism can cause serious diagnostic dilemma on FNAC and have been rarely documented. We present a case of 45-year-old female patient who clinically presented with diffuse thyroid swelling and features of hyperthyroidism. FNAC from thyroid swelling showed features of Hashimoto’s thyroiditis / Grave’s disease / Colloid goiter with follicular hyperplasia and at places raising the suspicion of malignant transformation. Further clinical evaluation of patient, it was found that she had carbimazole therapy. Correlating the clinical and cytomorphologic features, a diagnosis of “therapy induced (carbimazole) changes in hyperthyroidism was given.

查看原文本刊更多论文

甲亢患者卡咪唑治疗后甲状腺的FNAC:诊断困境

版权所有©2018phcog.net这是一篇基于知识共享署名4.0国际许可协议的开放获取文章。引用本文:Santosh T, Panwar H, Kumari B, Singh VY, Arora RD, Hussain N. FNAC:卡咪唑治疗甲状腺功能亢进的诊断困难。卫生报告，2018;7(1):38-40。抗甲状腺药物治疗是治疗甲状腺功能亢进患者的常规方法。治疗引起的甲状腺功能亢进的改变可导致FNAC的严重诊断困境，很少有文献记载。我们报告一例45岁的女性患者，临床表现为弥漫性甲状腺肿胀和甲状腺功能亢进的特征。甲状腺肿胀的FNAC表现为桥本甲状腺炎/格雷夫斯病/胶质甲状腺肿伴滤泡增生，可疑部位有恶性转化。进一步对患者进行临床评估，发现她曾接受卡咪唑治疗。结合临床和细胞形态学的特点，诊断为甲亢的“治疗性”(卡咪唑)改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology, Gastroenterology and Hepatology Reports

自引率

0.00%

发文量